亿帆医药取得一项药品注册证书

Core Viewpoint - The company has received approval for its injectable drug, Isavuconazole sulfate, from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable Isavuconazole sulfate on September 15, 2025 [1] - Isavuconazole sulfate is an anti-infective medication indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients [1]